US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026

$3,850.00$5,850.00

Published on: April 9, 2021
Clear
SKU: GMS-3201 Category:

OVERVIEW

The US Therapeutic Plasma Exchange Market is forecasted to reach 251.7 million by 2026, growing at a CAGR of 6.37% during the forecast period. Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements, rising prevalence of chronic diseases and technological advancements. COVID-19 is a global public health emergency that has affected almost every industry and with the need for urgent medicines for cure of the infection, demand for plasma has been on the rise and is expected to further rise in the future.

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026 1

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026 2

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026 3

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026 4

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026 5

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026 6

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026 7

US Therapeutic Plasma Exchange Market Size & Share by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Multiple Sclerosis, Myasthenia Gravis, Guillain Barre Syndrome, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) – 2021 to 2026 8

TABLE OF CONTENT

1 US Therapeutic Plasma Exchange Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 US Therapeutic Plasma Exchange Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 US Therapeutic Plasma Exchange Market – Market Forces
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Opportunities
4.2.3 Challenges
4.3 Porters Analysis of Market
4.3.1 Bargaining power of suppliers
4.3.2 Bargaining powers of customers
4.3.3 Threat of new entrants
4.3.4 Rivalry among existing players
4.3.5 Threat of substitutes

5 US Therapeutic Plasma Exchange Market – By Indication (Market Size – & million/billion)
5.1 Neurological Disorders
5.2 Hematology Disorders
5.3 Renal Disorders
5.4 Autoimmune Disorders
5.5 Metabolic Disorders

6 US Therapeutic Plasma Exchange Market – Entropy
6.1 New product launches
6.2 M&A’s, collaborations, JVs and partnerships

7 US Therapeutic Plasma Exchange Market Company Profile (Key Players)
7.1 Market Share, Company Revenue, Products, M&A, Developments
7.2 Company 1
7.3 Company 11 & more

8 US Therapeutic Plasma Exchange Market – Appendix
8.1 Sources
8.2 Abbreviations